Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Vaccines designed to produce a strong T cell response may help protect against current and future SARS-CoV-2 variants.
CoVac-1 induced T-cell responses in about 90% of immunocompromised people with impaired B-cell function.
The quick spread of the BA.2 subvariant is likely due to its greater infectiousness rather than its ability to evade the immune system.
NIAID is preparing for the possibility of future variants evading protection against currently available COVID-19 vaccines.
The benefits of achieving herd immunity thresholds have been less successful with respiratory viruses that continually mutate.
Researchers showed that B cells evolve after COVID-19 vaccination to help improve protection against SARS-CoV-2 over time.
The HVTN 302 trial is evaluating experimental vaccines that deliver stabilized HIV spike proteins.
An NIH-sponsored study assessed boosters for adults fully vaccinated with any authorized or approved COVID-19 vaccine.
The PreHevbrio vaccine produces higher antibody levels and offers faster protection.
The findings suggest boosters not only lengthen immunity but help broaden and strengthen the immune response.
None of the available coronavirus vaccines have been linked to increased risk of HIV acquisition or disease progression.
As schools reopen, parents have questions about when COVID-19 vaccines will be available for children under 12.
The vaccine regimen tested in the Imbokodo trial was similar to the J&J COVID-19 vaccine, but an mRNA approach may hold more promise.
The experimental vaccines use the same technology as the highly effective Moderna COVID-19 shot.
The results point the way toward a universal coronavirus vaccine that could prevent future pandemics.
People who received a canarypox vector vaccine regimen were no less likely than placebo recipients to acquire HIV.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.